Novartis buys Mallinckrodt''s FDA voucher for $100M but remains mum on where to use its 7th PRV
Novartis on Thursday confirmed to Endpoints News that it purchased a priority review voucher from bankrupt pharma company Mallinckrodt, but the Swiss-American multinational company declined to elaborate on how it plans to use this 7th PRV. Under the terms of the deal, PRV market leader Novartis agreed to pay $65
Novartis buys Mallinckrodt''s FDA voucher for $100M but remains mum on where to use its 7th PRV
Novartis on Thursday confirmed to Endpoints News that it purchased a priority review voucher from bankrupt pharma company Mallinckrodt, but the Swiss-American multinational company declined to elaborate on how it plans to use this 7th PRV. Under the terms of the deal, PRV market leader Novartis agreed to pay $65